Silence Therapeutics (SLN) Jefferies London Healthcare Conference 2024 summary

Recent achievements and technology differentiation

• Advanced two lead proprietary siRNA programs with unique linkers, sequences, and chemistry, supporting a strong intellectual property portfolio.

• Expanded global presence with offices in the UK, Germany, and the US, employing about 125 people.

• siRNA platform is positioned as differentiated from other programs due to its proprietary design.

Lp(a) program market potential and clinical insights

• Lp(a) affects 20% of the global population, representing a large, unmet medical need with no approved therapies.

• Cardiovascular societies now recommend Lp(a) testing at least once in adulthood, increasing patient identification.

• Phase 2 data showed over 90% peak Lp(a) reduction with a single targeted agent, and more than 80% time-averaged reduction at 36 weeks.

• Durability of effect was maintained, with over 70% reduction at 60 weeks and no new safety signals.

• Phase 3 trial is planned to start by mid-next year, with a focus on a composite primary endpoint and a 300 mg dose at a minimum 12-week interval.

Competitive landscape and physician feedback

• Lp(a) lowering is seen as a new paradigm in precision cardiovascular medicine, with siRNA therapies offering high potency, durability, and infrequent dosing.

• Physicians are eager for a therapy to offer patients, as current testing is limited by lack of treatment options.

• Infrequent dosing intervals (every 3–6 months) are considered attractive for both patients and providers.

• The field is evolving with multiple siRNA and oral regimens, but siRNA is noted for lack of drug-drug interactions.